OKN-007
Recurrent Glioblastoma Multiforme (GBM)
Key Facts
About Oblato
Oblato is a clinical-stage biotech company advancing OKN-007, a free radical scavenger, for the treatment of aggressive brain cancers. The company has secured key regulatory designations from the FDA, including Orphan Drug, Fast Track, and Rare Pediatric Disease designations, underscoring the significant unmet need in its target indications. Its development strategy includes both intravenous and oral formulations, with ongoing Phase 2 trials in recurrent GBM and plans for a trial in DIPG. As a private subsidiary of HLB Therapeutics, Oblato's progress is closely tied to the clinical success of its single lead candidate.
View full company profileAbout Oblato
Oblato is a clinical-stage biotech company advancing OKN-007, a free radical scavenger, for the treatment of aggressive brain cancers. The company has secured key regulatory designations from the FDA, including Orphan Drug, Fast Track, and Rare Pediatric Disease designations, underscoring the significant unmet need in its target indications. Its development strategy includes both intravenous and oral formulations, with ongoing Phase 2 trials in recurrent GBM and plans for a trial in DIPG. As a private subsidiary of HLB Therapeutics, Oblato's progress is closely tied to the clinical success of its single lead candidate.
View full company profileAbout Oblato
Oblato is a clinical-stage biotech company advancing OKN-007, a free radical scavenger, for the treatment of aggressive brain cancers. The company has secured key regulatory designations from the FDA, including Orphan Drug, Fast Track, and Rare Pediatric Disease designations, underscoring the significant unmet need in its target indications. Its development strategy includes both intravenous and oral formulations, with ongoing Phase 2 trials in recurrent GBM and plans for a trial in DIPG. As a private subsidiary of HLB Therapeutics, Oblato's progress is closely tied to the clinical success of its single lead candidate.
View full company profileAbout Oblato
Oblato is a clinical-stage biotech company advancing OKN-007, a free radical scavenger, for the treatment of aggressive brain cancers. The company has secured key regulatory designations from the FDA, including Orphan Drug, Fast Track, and Rare Pediatric Disease designations, underscoring the significant unmet need in its target indications. Its development strategy includes both intravenous and oral formulations, with ongoing Phase 2 trials in recurrent GBM and plans for a trial in DIPG. As a private subsidiary of HLB Therapeutics, Oblato's progress is closely tied to the clinical success of its single lead candidate.
View full company profileTherapeutic Areas
Other Recurrent Glioblastoma Multiforme (GBM) Drugs
| Drug | Company | Phase |
|---|---|---|
| Gliovac/ERC1671/SITOIGANAP | Epitopoietic Research | Phase 2 |
| Alpha DaRT | Alpha Tau Medical | Pre-Clinical |